Q BioMed Inc (QBIO)

[Whale Gunna]

$QBIO .015 INITIAL DD POST

A Meso1 OTC DD Package

Q BioMed Inc.
11/17/2022
- Whale Gunna’

Meso1OTC #Meso1MAFIA
Meso1 (@Meso1OTC) / Twitter
https://discord.gg/sUZKbh9qYA
Disclaimer
This DD package is not a solicitation to buy or sell the security “Q BioMed Inc.” Ticker symbol $QBIO. We were not paid to create or distribute this information and we do not take responsibility for your use of this information.
Overview
Q BioMed Inc. ''Q`` is a biomedical acceleration and development company focused on acquiring companies and biomedical assets in clinical stage or and near revenue development. Q Bio is dedicated to providing these target companies strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
Share Structure “SS”
Transfer Agent - VStock Transfer LLC
Market Cap
$1,560,069 (million)
Authorized Shares
250,000,000 (million)
Outstanding Shares
84,328,041 (million)
Held at DTC
74,141,916 (million)
Float
41,000,000 (per last report from June 2022, I fully expect the current float count to be HIGHER than this number, no estimate can be provided)



The Due Diligence “DD” Case for $QBIO

Q BioMed Inc. is, in my opinion, a strategic holding company for underutilized or undervalued assets within the medical industry. Q BioMed aims to acquire pre-existing companies or assets in the medical feild that they believe, being management, can turn around into a profitable business venture. This strategy by nature can become very lucrative for Q BioMed, as we will get into later on in the write up. This allows Q BioMed to diversify their investments within the industry and allows the company to skip many of the initial phases of development as they are aquiring pre exisiting medical development, as long as Q BioMed’s management team stays competent the company and it’s investors can realize the success of several of these investments.

One of the most exciting outlets within Q Biomed’s spear of influence regards a company called Mannin Research, here is a tid bit pulled out of a QBIO filing.

“On September 1, 2020, we further amended the license agreement allowing Mannin to grant an exclusive license to Mannin GmbH (its wholly owned German subsidiary) in order fully take advantage of the German government grant to Mannin. The agreement also confirms our ongoing investment into the Tie2 platform to create, and therefore maintain economic value for us and our shareholders. We have agreed to contribute funds in Mannin GmbH. We shall pay Mannin $1.5 million in cash payable in three instalments, thereof $0.7 million of which has been paid, $0.4 million of which was due on December 31, 2020 and $0.4 million to be paid by June 30, 2021. In addition, we paid to Mannin $0.75 million in shares of our common stock valued as of June 15, 2020, in full satisfaction of R&D payables, contracted by Mannin in development of the Tie2 platform. We continue to have the right to 100% of the revenues derived from the Mannin Tie2 technology platform, until such time that Mannin and its subsidiaries have independently raised at least $2 million in funds, at which time the parties have agreed to a profit share structure reducing our future capital commitments to Mannin R&D. “




This partnership came to blossom post covid era in November by this PR released by Q BioMed Inc.


“New York, New York - November 14, 202 - Q BioMed Inc. (QBIO)), Q BioMed Inc. (QBIO), a commercial stage biotechbiotechnology acceleration development company, a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its long-term royalty agreement into an equity stake in Mannin Research Inc. (MRI), a private Canadian controlled biotechnology company, based in Toronto, Ontario, Canada. The conversion results in two key outcomes: QBIO receives a 15% equity stake in the form of common shares in MRI at a current valuation of MRI at CAD$30 million, and a royalty payment of $20 million on realization of future net sales.
QBIO expects the value of its investment to increase, due to quantifiable near-term and medium-term catalysts, including the signing of commercialization agreements by MRI, and completion of clinical milestones as part of its drug development program. In addition, utilizing MRI’s internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI’s drug development pipeline and companion diagnostics, are estimated to achieve a net present value close to the billion-dollar mark as it moves from its near-term clinical milestones to commercial revenues.
To support its critical path to commercial success, MRI has already accessed over CAD$30M in non-dilutive capital from government funding sources with significantly more expected over the next 18 months. This funding has greatly de-risked the earlier stages of development, providing an accelerated path to market, and enabling the completion of technical milestones that in turn support the achievement of commercial milestones. This dependable cycle of investment and de-risking has added significant value to QBIO’s investment. Lastly, QBIO’s only obligation to contribute to future R&D expenditures in this platform totals USD$1.5million.
MRI’s drug development pipeline is positioned to be a multi-billion dollar blockbuster franchise for years to come. The pipeline includes two therapeutic modalities: large molecule (recombinant protein therapeutic) and small molecule drugs. The MRI pipeline addresses the unmet needs for patients in three initial indications: glaucoma, kidney disease, and ARDS.
The common thread for all three diseases is the treatment of an underlying vascular dysfunction that can be ameliorated by targeting the Ang1-Tie2 mechanism of action. In a context dependent manner, MRI has developed a series of drugs, as well as companion diagnostics for glaucoma and ARDS, respectively, to address the unmet needs of these patients.
Denis Corin, QBioMed CEO says, “The value of our investment into the Mannin pipeline to date is not recognized at all on our balance sheet. The conversion of our agreement to this value-based equity ownership allows us to immediately recognize approximately CAD$5.0 million in shareholder equity and we anticipate this value to grow substantially over the next 12 months. Our investment has contributed to the development of a blockbuster franchise of drugs and companion diagnostics addressing millions of patients with significant unmet needs. We expect this to translate into a very significant return on our investment capital.” He continued, “Mannin has a portfolio of drugs that has a total addressable market of over $150 billion per year. Multiple large pharma companies have indicated interest in bringing the Mannin drugs to patients in markets around the world. We expect that at least one major strategic deal will be announced by Q1 of 2023 and additional transformative economic transactions later in 2023, further validating the MRI drug pipeline and its blockbuster potential. These would be very significant value creating events for both QBIO and Mannin shareholders. QBIO is so proud to have been an integral part of this development from the beginning.”
Wether we are to believe those revenue targets in the “Billions” is definitely up for debate! And I believe those dollar figures are grossly over estimated the fact that Q BioMed has used the past 5 years, and the Covid crisis to settle debt obligations (unfortunately at the expense of past shareholders) along with receiving and utilizing NON-DILUTIVE funding streams positions the company and it’s stock at the end of 2022 and into 2023 in a very undervalued position, almost forgotten by the masses however Q BioMed’s efforts over these years do not seem to be in vain! And no matter what the past tries to dictate emtionally and pyschologically to be a sucessful trader we must ignore the noise and focus on the facts.

Here is a link that is worth a read - Major investments in domestic firms to rebuild Canada's biomanufacturing sector (newswire.ca)

The other noteworthy company in the Q BioMed pipeline is QBM-001. This company aims to address the dire needs for medical care and/or treatments in the non verbal autism disorder spectrum, a sector that unfortunately is set to grow immensly by 2026. - Autism Disorder and Treatment Market Size to Worth USD 4,612.1 Million by 2026 | Medgadget

The cost per non verbal child throughout their lifetime is nearly US $5,000,000 (million) “QBM-001 is designed to address multiple problems. One, it is designed to lower neurotoxins that build up in children with pediatric minimally verbal autism. Two, it may protect against signals that cause healthy neurons to die. And three, it may lower inflammation in the brain.”

“Collectively, these effects are designed to alleviate the condition and allow toddlers to actively develop language and speech, and avoid life-long speech and intellectual disabilities caused from being non-verbal.”


Q BioMed has already initated trials of their drug
Q BioMed Files for Orphan Drug Designation with U.S. FDA (globenewswire.com)

And currently is still in the pre-clinical trial stage but similar to their investment to mannin, years of developement along with surviving the covid pandemic offer a ripe time for the company to realize significant progress here at the end of 2022 and for 2023, this is yet another portion of Q BioMed that has become forgotten or “overlooked” by the masses.

If we are to look at QBIO from a valuation perspective, the current market cap is roughly US $1.6 Million dollars.. It shouldnt take a rocket scientist to realize how undervalued this is, EVEN if QBIO was simply an empty shell. Given the SS of the security it would not be impossible to fetch $1 million+ for the sole purpose of being a shell to merge the buying entities company(companies) into. However QBIO is far from a shell and has several ground breaking products either on the market or soon to be released to the market. In fact the latest PR alone represents a current valuation just from the 15% mannin stake of axp $4 million USD, along with up to $20 million in royalties from future sales. It is my opinion that once the market catches on to QBIO stock at these levels we may see an incredible run as a $1.6 million dollar market cap is incredibly laughable. I have seen this type of set-up countless times now over my years in the OTC.. QBIO eerily reminds me of DNR(G) which I purchased at .0045 per share before the share price realized prices in excess of .15 cents!

I understand many shareholders will be “bashing” or have a negative stance on this company Q BioMed but please remeber emotions in the stock market, and especially the OTC, will never make you a penny in your lifetime.. I had QBIO on my radar for many months now but I did not bother purchase or create a DD pack simply becuase we must wait for the set up to form. Many current holder purchased while converts were converting and the pps had no basis techinically to stop dropping. We call this a “falling knife” I believe at the current pps levels we are much closer to “logical bottom” and the potential rewards for me warrant the current risks imo. Here at Meso1OTC (#Meso1MAFIA) we will talk extenisively about these often unheard of trading techniques, along with emiotional/mental and even subconscious conditioning.

Being an introductory DD pack I have kept this one relatively short, please expect more to be compiled as we evaluate the trade along the way. Thank you for reading and best of luck out there!!! LFG


Link to join Meso1OTC again —> https://discord.gg/J7b3pMzap4